论文部分内容阅读
观察硫酸依替米星在老年感染性疾病中应用的安全性。择 6 2例年龄大于 6 0岁的老年感染性疾病病例 ,随机分成两组。硫酸依替米星组 ,单一用药 15例 ,联合用药 16例 ;阿米卡星组 ,单一用药 12例 ,联合用药 19例。记录用药前后血 GPT、BUN、Cr的变化及用药过程中的临床不良反应。结果 ,硫酸依替米星组与阿米卡星组的血 GPT、BUN、Cr在治疗前后无明显差异 (P>0 .0 5 ) ,而临床不良反应的发生率 ,硫酸依替米星组明显低于阿米卡星组 ,分别为 3.2 3%和 16 .13%。结论 :硫酸依替米星是一个毒性较低 ,安全有效的氨基糖苷类抗生素 ,可用于老年感染性疾病。
To observe the safety of etimicin sulfate in elderly infectious diseases. Sixty-two elderly infectious diseases older than 60 years were randomly divided into two groups. Etimicin sulfate group, a single drug in 15 cases, combined with 16 cases; amikacin group, a single drug in 12 cases, combined with 19 cases. The changes of GPT, BUN and Cr in blood and the clinical adverse reactions in the course of medication were recorded before and after treatment. Results There was no significant difference in GPT, BUN and Cr between etimicin and amikacin groups before and after treatment (P> 0.05). However, the incidence of clinical adverse reactions, etimicin sulfate group Significantly lower than the amikacin group, respectively 3.2 3% and 16.13%. Conclusion: Etimicin sulfate is a less toxic, safe and effective aminoglycoside antibiotic, which can be used in senile infectious diseases.